Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)-Reference-Cited by-同舟云学术

Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)

Published:2017-07 Issue: Volume:79 Page:119-128
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Lebellec Loïc,Chauffert Bruno,Blay Jean-Yves,Le Cesne Axel,Chevreau Christine,Bompas Emmanuelle,Bertucci François,Cupissol Didier,Fabbro Michel,Saada-Bouzid Esma,Duffaud Florence,Feuvret Loïc,Bonneville-Levard Alice,Bay Jacques-Olivier,Vauleon Elodie,Vinceneux Armelle,Noel Georges,Penel Nicolas,Mir Olivier

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Building a global consensus approach to chordoma: a position paper from the medical and patient community;Stacchiotti;Lancet Oncol,2015

2. Phase II study of imatinib in advanced chordoma;Stacchiotti;J Clin Oncol,2012

3. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor: Dasatinib Treatment of Indolent Sarcomas;Schuetze;Cancer,2017

4. Phase II study on lapatinib in advanced EGFR-positive chordoma;Stacchiotti;Ann Oncol,2013

5. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO);Bompas;Ann Oncol Off J Eur Soc Med Oncol ESMO,2015

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chordoma Genetic Aberrations and Targeted Therapies Panorama: A Systematic Literature Review;Journal of Clinical Medicine;2024-05-05

2. Pembrolizumab monotherapy for advanced chordoma – Authors' reply;The Lancet Oncology;2023-10

3. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial;The Lancet Oncology;2023-08

4. Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study;ESMO Open;2023-06

5. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression;Journal for ImmunoTherapy of Cancer;2023-04